What Defines a Value Stock?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.
Below is a list of notable value stocks in the healthcare sector:
- Lexicon Pharmaceuticals LXRX - P/E: 5.68
- Bio-Rad Laboratories BIO - P/E: 8.03
- Sanofi SNY - P/E: 9.7
- Cronos Group CRON - P/E: 2.53
- Innoviva INVA - P/E: 6.21
Lexicon Pharmaceuticals’s earnings per share for Q2 sits at -0.65, whereas in Q1, they were at -0.63. Lexicon Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Bio-Rad Laboratories has reported Q2 earnings per share at 1.61, which has decreased by 15.71% compared to Q1, which was 1.91. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Most recently, Sanofi reported earnings per share at 1.41, whereas in Q1 earnings per share sat at 1.8. Sanofi does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Cronos Group’s earnings per share for Q2 sits at -0.19, whereas in Q1, they were at 0.2. Cronos Group does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Innoviva has reported Q2 earnings per share at 0.69, which has increased by 16.95% compared to Q1, which was 0.59. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.